Close icon

Research

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

Posted on 25 November 2011
Author: admin@twk
Latest News From

The World of Cardiology

Explore the blog